All In Biotech

Drug Trial Radar · NCT00202566

Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

Evaluation of the Anti-anginal Efficacy and Safety of Oral Administration of Ivabradine Compared to Placebo on Top of Background Therapy With Atenolol in Patients With Stable Angina Pectoris. A Four-month Randomised Double-blind, Parallel Group International Multicentre Study.

Last checked: Nov 19, 2026Latest source record: Mar 15, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 750 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

750

Planned (sponsor's estimate)

Start

Jun 2005

Primary completion

Not stated

Study completion Oct 2007

Sponsor

Lead sponsor
Institut de Recherches Internationales ServierAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To test whether ivabradine when given in combination with atenolol is able to improve the exercise tolerance of patients with stable angina pectoris

Conditions

  • Angina Pectoris

Interventions

  • IvabradineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement between baseline and end of treatment of the treadmill exercise tolerance test

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Montreal Heart Institute

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.